AU2021270745A1 - IL-2 fusion polypeptide compositions and methods of making and using the same - Google Patents

IL-2 fusion polypeptide compositions and methods of making and using the same Download PDF

Info

Publication number
AU2021270745A1
AU2021270745A1 AU2021270745A AU2021270745A AU2021270745A1 AU 2021270745 A1 AU2021270745 A1 AU 2021270745A1 AU 2021270745 A AU2021270745 A AU 2021270745A AU 2021270745 A AU2021270745 A AU 2021270745A AU 2021270745 A1 AU2021270745 A1 AU 2021270745A1
Authority
AU
Australia
Prior art keywords
composition
polypeptide
certain embodiments
aqueous solution
nacl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2021270745A
Other languages
English (en)
Inventor
Francisca O. GBORMITTAH
Mayur Kalariya
Tarek A. Zeidan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mural Oncology Inc
Original Assignee
Mural Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mural Oncology Inc filed Critical Mural Oncology Inc
Publication of AU2021270745A1 publication Critical patent/AU2021270745A1/en
Assigned to MURAL ONCOLOGY, INC. reassignment MURAL ONCOLOGY, INC. Request for Assignment Assignors: ALKERMES PHARMA IRELAND LIMITED
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AU2021270745A 2020-05-11 2021-05-10 IL-2 fusion polypeptide compositions and methods of making and using the same Abandoned AU2021270745A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063022853P 2020-05-11 2020-05-11
US63/022,853 2020-05-11
PCT/US2021/031611 WO2021231316A1 (en) 2020-05-11 2021-05-10 Il-2 fusion polypeptide compositions and methods of making and using the same

Publications (1)

Publication Number Publication Date
AU2021270745A1 true AU2021270745A1 (en) 2022-12-15

Family

ID=78524918

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021270745A Abandoned AU2021270745A1 (en) 2020-05-11 2021-05-10 IL-2 fusion polypeptide compositions and methods of making and using the same

Country Status (12)

Country Link
US (1) US20210371486A1 (https=)
EP (1) EP4149515A4 (https=)
JP (1) JP2023525565A (https=)
KR (1) KR20230009446A (https=)
CN (1) CN115916242A (https=)
AU (1) AU2021270745A1 (https=)
BR (1) BR112022022764A2 (https=)
CA (1) CA3172871A1 (https=)
IL (1) IL298065A (https=)
MX (1) MX2022014164A (https=)
TW (1) TW202207970A (https=)
WO (1) WO2021231316A1 (https=)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1292686C (en) * 1986-10-27 1991-12-03 Ze'ev Shaked Pharmaceutical compositions of recombinant interleukin-2 and formulation process
SK11142002A3 (sk) * 1999-12-30 2004-09-08 Chiron Corporation Liečivo na podávanie interleukínu-2 a stabilizovaný lyofilizovaný alebo sprejovo sušený farmaceutický prostriedok s obsahom interleukínu-2
CN1816356A (zh) * 2003-05-14 2006-08-09 免疫原公司 药物缀合物组合物
JP2006137678A (ja) * 2004-11-10 2006-06-01 Shionogi & Co Ltd インターロイキン−２組成物
US9156897B2 (en) * 2012-06-08 2015-10-13 Alkermes, Inc. Fusion polypeptides comprising an active protein linked to a mucin-domain polypeptide
US10016415B2 (en) * 2014-08-18 2018-07-10 Alkermes Pharma Ireland Limited Aripiprazole prodrug compositions
AU2015364396B2 (en) * 2014-12-19 2018-08-09 Alkermes, Inc. Single chain Fc fusion proteins
WO2019019998A1 (zh) * 2017-07-25 2019-01-31 江苏恒瑞医药股份有限公司 一种il-15蛋白复合物药物组合物及其用途
US20210038684A1 (en) * 2019-06-11 2021-02-11 Alkermes Pharma Ireland Limited Compositions and Methods for Cancer Immunotherapy
BR112022007158A2 (pt) * 2019-10-18 2022-07-05 Alkermes Pharma Ireland Ltd Agentes imunomodulatórios de il-2 em combinação com inibidores do ponto de verificação imunológico
EP4093755A4 (en) * 2020-01-24 2024-07-31 Alkermes Pharma Ireland Limited PURIFICATION PROCESSES

Also Published As

Publication number Publication date
KR20230009446A (ko) 2023-01-17
CA3172871A1 (en) 2021-11-18
CN115916242A (zh) 2023-04-04
EP4149515A4 (en) 2023-12-06
BR112022022764A2 (pt) 2023-01-17
JP2023525565A (ja) 2023-06-16
IL298065A (en) 2023-01-01
MX2022014164A (es) 2023-02-22
TW202207970A (zh) 2022-03-01
WO2021231316A1 (en) 2021-11-18
US20210371486A1 (en) 2021-12-02
EP4149515A1 (en) 2023-03-22

Similar Documents

Publication Publication Date Title
RU2550271C2 (ru) Иммуногенная композиция для лечения или профилактики clostridium difficile, способ ее получения и способ индукции иммунного ответа к c. difficile
EP4065085A1 (en) Bicyclic peptide ligands specific for epha2 and uses thereof
KR102720834B1 (ko) Il-15 단백질 복합체 약학 조성물 및 이의 용도
RS55772B1 (sr) Stabilizacija fsh
CN112516090B (zh) 抗体偶联药物的药物组合、冷冻干燥剂及制备方法、用途
KR20210113271A (ko) 콜라게나제 제형 및 이의 제조 방법
US20210179690A1 (en) Ctla4-ig fusion protein formulation
JPH0314520A (ja) インターロイキン―１組成物
TW200303756A (en) Lyophilised preparation comprising immunocytokines
WO2022157806A1 (en) Freeze dried antibody formulations and methods thereof
US20210371486A1 (en) Il-2 fusion polypeptide compositions and methods of making and using the same
US20200299371A1 (en) Pharmaceutical composition comprising pegylated fab' fragment of anti-human ngf antibody
WO2021231319A1 (en) Il-2 fusion polypeptide compositions and methods of making and using the same
US20250302919A1 (en) Pharmaceutical compositions of efruxifermin
CN116077646A (zh) 一种抗冠状病毒s蛋白的抗体制剂及其制备方法和用途
Gour et al. Development and evaluation of metronidazole injection by mixed solvency approach
JP2005060377A (ja) インターロイキン−１１含有凍結乾燥製剤
BR122025026726A2 (pt) Composições farmacêuticas de interleucina-15 humana heterodimérica, uso e método de preparação das mesmas, bem como forma de dosagem, frasco, seringa, kit, autoinjetor e produto farmacêutico
CN117355321A (zh) 增强性能的赋形剂以及降低生物制剂的粘度和提高生物制剂的稳定性的方法
EA045592B1 (ru) Жидкий препарат, содержащий антитело к il-17

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: MURAL ONCOLOGY, INC.

Free format text: FORMER APPLICANT(S): ALKERMES PHARMA IRELAND LIMITED

MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period